IVI Fosters a Middle Ground for Value Assessment Discussions

In an article published on AJMC.com, IVI’sJennifer Bright and Mark Linthicum argue value assessment stakeholders need to have transparent discussions about value assessment and understand what value means from other points of view. Read the full article here.

Is One Answer Good Enough for All? Defining Value in Healthcare

While it makes sense for value assessment to be woven into healthcare decision making, relying on a single method to measure value and using this metric to restrict treatment access is shortsighted. IVI’s Jennifer Bright and Mark Linthicum address this concern in a recent article for the American Journal of Managed Care (AJMC). Read the […]

IVI Provides Insight into CVS Health’s Decision to Include Cost-per-QALY Analyses from ICER into Formulary Decision-Making

CVS Health’s pharmacy benefit management (PBM) division, CVS Caremark, recently announced their decision to rely exclusively on the analyses of the Institute for Clinical and Economic (ICER) in a new drug management program. IVI’s Director of Scientific Communications, Mark Linthicum, responds to this story in MedCity stating, “The neat ‘answer’ regarding the value of treatment […]

Why Quality Measures Must Reflect Patient Values, Care Experience

There isn’t an easy answer to assessing value in healthcare, but IVI is working to tackle the problems through considerable research and experimentation by developing an open-source value platform that considers no only clinical factors, but patient perspectives as well. In a recent interview with PatientEngagementHIT.com, IVI’s Jennifer Bright (Executive Director) and Mark Linthicum (Director […]

Is Using Centralized Value Assessment to Make Centralized Pricing Decisions the Most Effective Path Forward?

The Pink Sheet article described comment letters to HHS’ drug pricing blueprint recommending that cost-effectiveness analyses by ICER could help promote value-based pricing in government-sponsored insurance. While IVI concurs value assessment is noble, worthwhile and needed, IVI cautions about making centralized pricing decisions based on centralized value assessments within the U.S.’s current decentralized health care […]

How to Improve Value Assessment

In an op-ed published in Healthcare Business News, IVI’s Executive Director, Jennifer Bright, describes four essential steps necessary to better measure value in healthcare: Better value measurement must incorporate the patient perspective into all assessment tools. Real world data must be considered when determining a treatment’s worth beyond direct clinical benefit. Value assessments must be […]

IVI Leadership Invited to Speak at the 2018 BIO International Convention

The 2018 BIO International Convention will be held in Boston, MA from June 4th through June 7th. IVI’s Jennifer Bright (Acting Executive Director) and Mark Linthicum (Director of Scientific Communications) are among the speakers invited to the 2018 BIO International Convention, where they will be discussing value assessment frameworks and patient value. The description of […]